CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

filgotinib

Last Updated: July 6, 2020
Result type: Reports
Project Number: SR0656-000
Product Line: Common Drug Review

Generic Name: filgotinib

Brand Name: TBC

Manufacturer: Gilead Sciences Canada, Inc.

Indications: Arthritis, Rheumatoid

Manufacturer Requested Reimbursement Criteria1: Indicated as monotherapy, or in combination with methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), for reducing signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.

Submission Type: New

Project Status: Pending

Call For Patient Input: July 6, 2020

Patient Input Closed: August 25, 2020

Anticipated Date: August 4, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback